Navigation Links
Quebec City researchers pave the way for novel treatment of pulmonary hypertension

Montreal - A Heart and Stroke Foundation researcher has discovered what could be the first truly effective breakthrough in the diagnosis and treatment of pulmonary hypertension, a devastating, life-threatening condition which results in an enlargement of the heart.

"We have discovered an early warning system in a protein called PIM-1," Dr. Sbastien Bonnet told the Canadian Cardiovascular Congress 2010, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.

Dr. Bonnet has established that the PIM-1 cells can be used as markers of pulmonary hypertension.

"Blood samples were taken from patients to measure PIM-1 expression in the blood," says Dr. Bonnet, who is a professor at Laval University and a researcher at Centre hospitalier universitaire de Qubec. "We were surprised to find that the greater the PIM-1 levels, the more severe the pulmonary hypertension in the patient."

He says this opens the doors to using regular blood tests to look at PIM-1 levels. "If there is a slight increase in PIM-1, we will know that something is going on." This is important since the condition is under-diagnosed and often not discovered until it is in a late stage. Without earlier treatment it has a very poor prognosis. The condition has traditionally been diagnosed by a six minute walking test.

PIM-1 also offers the opportunity to move beyond the diagnosis of pulmonary hypertension to treatment. By blocking the PIM-1 protein, researchers were able to reverse the condition.

"This is a remarkable finding," says Dr. Bonnet. "We have found that using gene therapy to inhibit the inappropriate activation of this protein is a novel and effective therapy that can reverse the disease altogether."

Before this discovery there has been no agent to reverse the disease. Current drug treatments can improve quality of life but to this date there has been nothing that can cure the disease.

"Pulmonary hypertension is a rare but life-threatening condition," says Heart and Stroke Foundation spokesperson Dr. Beth Abramson. "These are often very sick individuals. By the time a patient gets to a doctor, the disease is usually well established." Individuals at increased risk of developing pulmonary hypertension include those with a family history and people with a history of blood clots in the lungs (pulmonary embolism).

She recommends that patients pay particular attention to any symptoms like shortness of breath or extreme tiredness. "There are treatments that can help patients live longer, healthier lives."

Pulmonary hypertension is abnormally high blood pressure in the pulmonary arteries, the arteries which carry blood from the heart to the lungs. The condition makes it more difficult for blood to flow to the lungs, causing shortness of breath, fatigue, and swelling of the feet and ankles. It can make everyday tasks almost impossible.

The number of Canadians with pulmonary hypertension is difficult to estimate, because it is under-diagnosed and the early symptoms are common to other conditions such as asthma and general fatigue. In addition, few studies have been conducted.


Contact: Jane-Diane Fraser
613-569-4361 x273
Heart and Stroke Foundation of Canada

Related medicine news :

1. Mount Sinai researchers discover origin of immune cells in the brain
2. UC San Diego researchers identify factor boosting leukemias aggressiveness
3. UCI stem cell researchers to receive $9.35 million in state funding
4. Researchers find better method to help mothers cope with childs cancer and related stress
5. Researchers advocate for more education and attention regarding rare breast cancer
6. Mount Sinai researchers discover why cocaine is so addictive
7. Temperature rhythms keep body clocks in sync, UT Southwestern researchers find
8. Need a study break to refresh? Maybe not, say Stanford researchers
9. Researchers reach consensus on use of deep brain stimulation to treat Parkinsons
10. AACR to honor leading researchers at breast cancer symposium
11. Medical researchers break down costs to care for heart failure patients at the end of life
Post Your Comments:
(Date:12/1/2015)... ... 2015 , ... Next IT Healthcare, the leader in patient ... year’s Fierce Innovation Awards: Healthcare Edition, an awards program from the publisher of ... the category of Digital Solutions for its innovative, industry-leading product, Alme Health Coach. ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... Lutronic, a ... of Clarity, the latest addition to the devices for sale in the United States. ... nm Alexandrite and long-pulsed 1064 nm Nd:YAG lasers, into a single platform that is ...
(Date:12/1/2015)... ... December 01, 2015 , ... PYA’s ... Post-Affiliation Integration ,” addresses a main “pain point” for merging or aligning healthcare ... once a deal is signed. This quick-read guidance suggests that failing to ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... SACC-GA and SACC-USA through membership and leadership since 2008. Gary Bruce, President ... SACC-USA . Gary has spent a significant amount of time in Sweden ...
(Date:12/1/2015)... ... December 01, 2015 , ... Nurotron Biotechnology Co., Ltd., ... largest order to date. , The order will be from the China Disabled ... Cochlear Implant System is an effective solution for children and adults suffering from ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Sensor Networks, a leader in intelligent sensors and analytic software for sensor network-based systems, announced ... data collection of vital signs. Photo - ... ... ... ...
(Date:12/1/2015)... , Dec. 1, 2015 Ampio Pharmaceuticals, ... York Stock Exchange has established January 5, 2016 as the ... stockholders of the shares of Common Stock of Aytu ... share of Aytu common stock for every five (5) ... record date, December 1, 2015. The distribution date will be ...
(Date:12/1/2015)... Sweden , December 1, 2015 ... International Breast Cancer Study Group (IBCSG, Bern ... ) to be part of a state of the ... cancer drug.  --> --> ... cancer being treated with anti-hormonal therapy in combination with palbociclib, ...
Breaking Medicine Technology: